Cure Genetics Signs a Collaboration and License Agreement with Frametact to Develop Gene Therapy for Familial Neurological Diseases
Shots:
- Cure Genetics will receive $60M up front and milestones & continue to receive sales royalties based on net revenue upon the market launch of the product
- This collaboration will combine the extensive expertise of Frametact in the domain of neurological diseases with Cure Genetics' leading technology VELP platform in AAV vector development and efficient in vivo AAV screening for the treatment of familial neurological diseases.
- Additionally, Cure Genetics continues to work with Frametact to expand the development of gene therapy products for brain diseases & also develops treatments for familial neurodegenerative diseases ie., Alzheimer's, Parkinson's, and Huntington's disease
Ref: PR Newswire | Image: Cure Genetics
Related News:- Regeneron to Acquire Decibel Therapeutics to Advance Gene Therapy and Hearing Loss Programs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
